Warhound Raises US$ 200M to Engineer Genetically Modified Military Dogs
A joint venture between Colossal Biosciences, famous for its mammoth and dire wolf de-extinction projects, and Anduril, a defense technology powerhouse, has just emerged from stealth with an ambitious and controversial plan: generate, clone, and genetically enhance a new generation of military dogs for the United States Armed Forces.
The startup, called Warhound and announced on October 22, 2026, has already raised $200 million in seed funding — including investments from Sequoia Capital, 8VC, Corner Ventures, and In-Q-Tel, the venture capital arm of the CIA. The round valued the company at $1.2 billion.
The problem no drone can solve
Warhound's premise is straightforward but no less urgent. Since 1942, when the U.S. Army created the K-9 Corps, working dogs have played an irreplaceable role in bomb detection, search and rescue, tactical reconnaissance, and patrol protection. According to the company's own figures, the current program encompasses more than 2,200 dog-handler teams, but relies overwhelmingly — more than 80% — on European suppliers, primarily from the Netherlands and Germany.
The problem is that the European supply is drying up. Elite working dog breeding, particularly of Belgian Malinois and German Shepherds, faces chronic problems: hip dysplasia, predisposition to certain cancers, premature vision loss, and a training dropout rate of up to 55%. Half of the dogs that arrive in the United States from Europe are deemed unfit for service after three years of acquisition and training. At least some of those that fail are euthanized.
"We know a lot about canine genetics," Ben Lamm, CEO of Colossal Biosciences, told Fortune. "Humans have bred dogs for traits for centuries, sometimes introducing positive and sometimes negative mutations. We can go in and remove mutations that cause muscle atrophy or hip dysplasia, or improve genes for agility or even longevity."
The strategy: biobank, editing, and cloning
Warhound's plan breaks down into three stages. First, the company has already collected blood samples from high-performing military, police, and emergency-response dogs — predominantly Belgian Malinois, some Labrador Retrievers, and Shepherds. These cell lines were stored in a biobank.
The second stage has already begun. Colossal scientists are editing the genes of these cell lines, removing mutations associated with common diseases and adding characteristics that improve health, speed, agility, and — in the near future — olfactory capacity. Lamm told TechCrunch about the possibility of incorporating wolf olfactory receptor genes, an echo of Colossal's dire wolf de-extinction project.
The third stage is cloning. Viagen, another company in the Colossal group, will partner in the cloning of the edited dogs. The first litters are expected to be born in early 2027. The goal is for the dogs to be in service within two years.
Anduril and hardware: no cyborgs
The technological side of the project falls to Anduril, the defense company founded by Palmer Luckey — the same creator of the Oculus Rift who, in 2024, brought Anduril into an AI contract with the Pentagon alongside OpenAI. Warhound does not plan to create cyborgs. The idea is to equip the dogs with "advanced cybernetic augmentations": bulletproof vests with sensors that transmit data to handlers, eye and ear protection, and battlefield awareness systems integrated with Anduril's Eagle Eye mixed-reality helmet.
"If we make the dog safer, healthier, and better-prepared to perform, it's going to perform better on duty," Lamm told TechCrunch. "Anduril's additions make the dogs safer and healthier beyond genetics — on top of the dog, not in the dog."
The partnership is symmetrical: Colossal holds equity in Warhound and licenses the genetic technology, while Anduril provides the hardware. Luckey is a partner but has no equity stake in the startup. The CEO is David Spirk, a former Marine, former Pentagon chief data officer, and most recently an engineer at Palantir.
The ethical and geopolitical weight
Warhound operates under the guidance of the American Humane Society, which will help certify the training program — a detail the company repeatedly highlights to ensure animal welfare standards are maintained. But the very idea of "genetic engineering applied to military dogs" raises questions that extend beyond animal welfare: who decides which characteristics are "enhanced"? How will the export of these genetically modified animals be regulated? And what impact will it have on security forces in countries that cannot compete with a $200 million budget?
Lamm emphasized that the goal is to rebuild the United States' domestic supply, not to create living weapons. "The idea is that if we make the dog healthier and better prepared, it will survive training and service better," he said. "This could be transformative for ensuring dogs make it through training."
The geopolitical landscape also matters. With China rapidly expanding its own defense technology program and European allies facing canine breeding shortages, the race for domestic military dog supply could become a new theater of technological competition — not for satellites or missiles, but for genomes.
The first batch of edited and cloned dogs should be born in January 2027. If everything goes as planned, the first "warhounds" will be patrolling U.S. military bases by 2028. What happens when man's best friend is enhanced by science beyond what nature — or natural selection — could achieve is something the world has yet learned to ask.
Sources: TechCrunch, Semafor, Fortune
✓ Independent sources cross-checked and verified before publishing
